On October 30, Xi'an Xintong Pharmaceutical Research Co., Ltd. held a press conference in the Silk Road Innovation and Smart Valley of Xi'an High-tech Zone to announce the approval of "Xinshi Mu," a first-class innovative drug targeting hepatitis B. It is the commercial name approved for the drug Preadfovir mesylate tablets, which is indicated for the treatment of chronic hepatitis B in adults.

The drug utilizes the HepDirect liver-targeted delivery system to concentrate the active ingredients in the target organ, enhancing efficacy and reducing toxicity. This makes it the world's first approved liver-targeted innovative drug for hepatitis B. Zhang Denge, chairman of Xintong Pharmaceutical, stated that "Xinshi Mu" is part of the national major new drug creation projects during the 12th and 13th Five-Year Plans, with research beginning in 2011, and it took 13 years to gain approval for market release.

Wang Liping, the Drug Safety Director of the Shaanxi Provincial Drug Administration, noted that the successful development of "Xinshi Mu" represents a breakthrough for local pharmaceutical companies in Shaanxi in terms of intellectual property for first-class innovative drugs, marking a significant advancement in China’s drug treatment capabilities for liver diseases since the implementation of the revised "Drug Registration Management Measures."

As a leading industry in Xi'an High-tech Zone, the biomedicine sector has formed an industrial cluster led by key enterprises such as Xi'an Janssen Pharmaceutical Co., Ltd. and Xi'an Juzi Biological Gene Technology Co., Ltd., with over 5,000 biopharmaceutical business entities collaborating. This has created a comprehensive ecological system showcasing large-scale industry, strong innovation capabilities, and a favorable industry ecosystem.

https://finance.eastmoney.com/a/202411053228709955.html